B-Lymphocyte Depletion With Rituximab and β-Cell Function: Two-Year Results
B-Lymphocyte Depletion With Rituximab and β-Cell Function: Two-Year Results
About this item
Full title
Author / Creator
Pescovitz, Mark D. , Greenbaum, Carla J. , Bundy, Brian , Becker, Dorothy J. , Gitelman, Stephen E. , Goland, Robin , Gottlieb, Peter A. , Marks, Jennifer B. , Moran, Antoinette , Raskin, Philip , Rodriguez, Henry , Schatz, Desmond A. , Wherrett, Diane K. , Wilson, Darrell M. , Krischer, Jeffrey P. , Skyler, Jay S. , the Type 1 Diabetes TrialNet Anti-CD20 Study Group and Type 1 Diabetes TrialNet Anti-CD20 Study Group
Publisher
Alexandria, VA: American Diabetes Association
Journal title
Language
English
Formats
Publication information
Publisher
Alexandria, VA: American Diabetes Association
Subjects
More information
Scope and Contents
Contents
We previously reported that selective depletion of B-lymphocytes with rituximab, an anti-CD20 monoclonal antibody, slowed decline of β-cell function in recent-onset type 1 diabetes mellitus (T1DM) at 1 year. Subjects were followed further to determine whether there was persistence of effect.
Eighty-seven subjects (aged 8-40 years) were randomly...
Alternative Titles
Full title
B-Lymphocyte Depletion With Rituximab and β-Cell Function: Two-Year Results
Authors, Artists and Contributors
Author / Creator
Greenbaum, Carla J.
Bundy, Brian
Becker, Dorothy J.
Gitelman, Stephen E.
Goland, Robin
Gottlieb, Peter A.
Marks, Jennifer B.
Moran, Antoinette
Raskin, Philip
Rodriguez, Henry
Schatz, Desmond A.
Wherrett, Diane K.
Wilson, Darrell M.
Krischer, Jeffrey P.
Skyler, Jay S.
the Type 1 Diabetes TrialNet Anti-CD20 Study Group
Type 1 Diabetes TrialNet Anti-CD20 Study Group
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3898764
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3898764
Other Identifiers
ISSN
0149-5992,1935-5548
E-ISSN
1935-5548
DOI
10.2337/dc13-0626
